Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.7% |
| 2 | Financials | 7.47% |
| 3 | Consumer Discretionary | 6.7% |
| 4 | Communication Services | 6.02% |
| 5 | Healthcare | 4.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2826
nCino
NCNO
$2.26B
| $2.27M | ﹤0.01% |
88,419
-305,433
| -78% | -$7.76M |
|
2827
Capital City Bank Group
CCBG
$898M
| $2.27M | ﹤0.01% |
53,215
+3,498
| +7% | +$146K |
|
|
XHR
2828
Xenia Hotels & Resorts
XHR
$1.76B
| $2.26M | ﹤0.01% |
159,685
+4,471
| +3% | +$61K |
|
|
SA
2829
Seabridge Gold
SA
$3.46B
| $2.26M | ﹤0.01% |
76,258
-48,134
| -39% | -$1.27M |
|
2830
Insperity
NSP
$2.05B
| $2.26M | ﹤0.01% |
58,242
-78,816
| -58% | -$3.15M |
|
2831
Univest Financial
UVSP
$1.19B
| $2.25M | ﹤0.01% |
68,638
+12,450
| +22% | +$390K |
|
2832
Ecovyst
ECVT
$1.1B
| $2.24M | ﹤0.01% |
230,351
-17,882
| -7% | -$156K |
|
|
EA
2833
CALL
DELISTED
Electronic Arts
EA
| $2.23M | ﹤0.01% |
10,900
-10,600
| -49% | -$2.14M |
|
2834
ACV Auctions
ACVA
$1.35B
| $2.23M | ﹤0.01% |
277,446
+32,561
| +13% | +$263K |
|
2835
PUT
Cytokinetics
CYTK
$10.2B
| $2.22M | ﹤0.01% |
+35,000
| New | +$2.18M |
|
2836
Bank First Corp
BFC
$1.76B
| $2.22M | ﹤0.01% |
18,204
+3,885
| +27% | +$495K |
|
2837
NCR Voyix
VYX
$1.17B
| $2.21M | ﹤0.01% |
216,733
+20,272
| +10% | +$220K |
|
2838
Vir Biotechnology
VIR
$1.52B
| $2.21M | ﹤0.01% |
365,826
-44,580
| -11% | -$265K |
|
2839
PUT
GitLab
GTLB
$7.32B
| $2.2M | ﹤0.01% |
58,700
| – | – |
|
2840
Aquestive Therapeutics
AQST
$533M
| $2.2M | ﹤0.01% |
340,807
+209,049
| +159% | +$1.3M |
|
2841
Allient
ALNT
$1.86B
| $2.2M | ﹤0.01% |
40,890
+2,175
| +6% | +$114K |
|
2842
Valvoline
VVV
$4.31B
| $2.2M | ﹤0.01% |
75,581
-62,619
| -45% | -$2.01M |
|
2843
Brady Corp
BRC
$4.43B
| $2.2M | ﹤0.01% |
28,011
+27,593
| +6,601% | +$2.14M |
|
2844
Dime Commercial Bancshares
DCOM
$1.82B
| $2.19M | ﹤0.01% |
72,850
+14,050
| +24% | +$406K |
|
2845
J&J Snack Foods
JJSF
$1.7B
| $2.19M | ﹤0.01% |
24,230
-487
| -2% | -$44.2K |
|
|
BRSP
2846
BrightSpire Capital
BRSP
$629M
| $2.18M | ﹤0.01% |
389,372
+25,842
| +7% | +$142K |
|
2847
Westamerica Bancorp
WABC
$1.39B
| $2.18M | ﹤0.01% |
45,527
+6,571
| +17% | +$315K |
|
2848
Capital Southwest
CSWC
$1.61B
| $2.16M | ﹤0.01% |
+97,739
| New | +$2.06M |
|
2849
PUT
Peloton Interactive
PTON
$2.44B
| $2.16M | ﹤0.01% |
350,000
| – | – |
|
2850
John Wiley & Sons Class A
WLY
$2.63B
| $2.15M | ﹤0.01% |
70,062
+4,672
| +7% | +$165K |
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $49.1B in Q4 2025, closing 641 positions and reducing 1,715 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.